Krilogy Financial’s Avadel Pharmaceuticals AVDL Stock Holding History

Krilogy Financial’s Portfolio AVDL Stock Details AVDL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-15,082	Closed	-$325K	–	989
2025 Q4	$325K	Buy	15,082 +6	+0%	+$116	0.01%	694
2025 Q3	$286K	Buy	+15,076	New	+$196K	0.01%	700
2025 Q1	–	Sell	-26,362	Closed	-$277K	–	224
2024 Q4	$277K	Buy	26,362 +9,200	+54%	+$112K	0.02%	213
2024 Q3	$225K	Sell	17,162 -100	-0.6%	-$1.52K	0.02%	212
2024 Q2	$243K	Buy	+17,262	New	+$281K	0.02%	220

Other funds holding AVDL

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $20.6B AUM 34.61% 1-Year Est. Return

Krilogy Financial's AVDL Position: Q1 2026 in Review

Krilogy Financial sold out of Avadel Pharmaceuticals (AVDL) in Q1 2026, closing a stake of 15,082 shares — an estimated $325K sold.

Krilogy Financial first reported a position in AVDL in Q2 2024 and held it in 5 quarters. The position peaked at $325K in Q4 2025. 2 funds tracked by Wall St. Rank hold AVDL as of Q1 2026.

Krilogy Financial reported no remaining Avadel Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
Krilogy Financial sold 15,082 Avadel Pharmaceuticals shares in Q1 2026, an estimated $325K.
Krilogy Financial first reported a position in Avadel Pharmaceuticals in Q2 2024 and held it in 5 quarters.
Krilogy Financial's Avadel Pharmaceuticals position peaked at $325K in Q4 2025.
2 funds tracked by Wall St. Rank held Avadel Pharmaceuticals as of Q1 2026.

Based on Krilogy Financial's 13F filing for Q1 2026, filed 17 Apr 2026.